HRTX News and Press, Heron Therapeutics Inc. From 12/20/22

Summary With two established FDA-approved therapies, Heron has a significant base of recurring revenues. Heron is working to get its third approved therapy onto an acceptable performance track. Heron's fourth approved therapy will be launching in Q1, 2023. Despite its approved t...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s finally some respite for investors in the stock market. Businesses have been struggling with rising prices over the past year. However, the market still has plenty of pessimism, with multiple undervalued penn...

Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference PR Newswire SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving...

Heron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Conference Call November 08, 2022, 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - CEO and Chairman John Poyhonen - President and Chief Commercial Officer Conference Call Participa...

Heron Therapeutics press release ( NASDAQ: HRTX ): Q3 GAAP EPS of -$0.38 in-line. Revenue of $26.56M (+14.3% Y/Y) misses by $0.4M . Heron currently expects FY 2022 net product sales for the oncology care franchise of $93M to $95M, unchanged from prior outlook. ...

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates PR Newswire - APONVIE ™ approval by FDA, U.S. launch planned for Q1 2023 – - ZYNRELEF ® ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful. However, everyone must realize that...

Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 PR Newswire SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the...

Summary Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that Pacira is working to address and growth should resume in the following qua...